RxDoctor Payments Data

Jordan Mahan

Family · Greenville, TXNPI 1215225057

Payments from drug & device makers

$4,960in general payments, 2019–2025

Across 235 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$1K
  • AstraZeneca$848
  • AbbVie$796
  • Novo Nordisk$287
  • Lilly USA, LLC$260
  • GSK$144
  • plus $1K from 26 others

What the payments were for

  • Consulting fees$80016%
  • Travel & lodging$3046%
  • Food & beverage$3,78376%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,960 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$65,063
Medicare patients
244
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide115$134,144
EliquisApixaban40$66,847
OzempicSemaglutide29$47,292
FarxigaDapagliflozin Propanediol31$25,988
JanuviaSitagliptin Phosphate23$23,883
TrulicityDulaglutide16$23,296
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$17,882
MyrbetriqMirabegron25$15,409
Tresiba Flextouch U-100Insulin Degludec14$15,400
Janumet XrSitagliptin Phos/Metformin Hcl12$15,059
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$9,839
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,081
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,140
ImvexxyEstradiol19$6,426
SymbicortBudesonide/Formoterol Fumarate11$4,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$260$157,440131 claims
PfizerEliquis$94$66,84740 claims
Novo NordiskOzempic$287$47,29229 claims
MerckJanuvia, Janumet Xr$41$38,94235 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$848$38,04353 claims
GSKTrelegy Ellipta, Anoro Ellipta$144$27,72231 claims
Astellas Pharma US IncMyrbetriq$98$15,40925 claims
AbbVieSynthroid$796$2,29231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Greenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →